The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn's disease

References

• Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 2008;14:390–400.
   PubMed Web of Science ®Google Scholar
• van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443–8.
   PubMed Web of Science ®Google Scholar
• Strober W, Zhang F, Kitani A, Fuss I, Fichtner-Feigl S. Proinflammatory cytokines underlying the inflammation of Crohn's disease. Curr Opin Gastroenterol 2010;26:310.
   PubMed Web of Science ®Google Scholar
• Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22–8.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323–33.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232–9.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van AG, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND Trial. Gastroenterology 2012;142:1102–1111.
   PubMed Web of Science ®Google Scholar
• Van AG, Vermeire S, Rutgeerts P. Mucosal healing and anti TNFs in IBD. Curr Drug Targets 2010;11:227–33.
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, Results from the 2nd Scientific Workshop of the ECCO (I): impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011;5:477–483.
   PubMed Web of Science ®Google Scholar
• Daperno M, Castiglione F, de RL, Dotan I, Farkkila M, Florholmen J, Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis 2011;5:484–98.
   PubMed Web of Science ®Google Scholar
• Kiss LS, Szamosi T, Molnar T, Miheller P, Lakatos L, Vincze A, Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther 2011;34:911–22.
   PubMed Web of Science ®Google Scholar
• Fuss IJ. Is the Th1/Th2 paradigm of immune regulation applicable to IBD? Inflamm Bowel Dis 2008;14:S110–12.
   PubMed Web of Science ®Google Scholar
• Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52:65–70.
   PubMed Web of Science ®Google Scholar
• Olsen T, Rismo R, Cui G, Goll R, Christiansen I, Florholmen J. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine 2011;56:633–40.
   PubMed Web of Science ®Google Scholar
• Holtta V, Klemetti P, Sipponen T, Westerholm-Ormio M, Kociubinski G, Salo H, IL-23/IL-17 immunity as a hallmark of Crohn's disease. Inflamm Bowel Dis 2008;14:1175–84.
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Vandemeulebroecke M, Reinisch W, Higgins PDR, Wehkamp J, Inhibition of IL-17A by secukinumab is ineffective for Crohn's disease (CD). J Crohns Colitis 2011;5:S7.
   Google Scholar
• Olsen T, Cui G, Goll R, Husebekk A, Florholmen J. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol 2009;44:727–35.
   PubMed Web of Science ®Google Scholar
• Arijs I, Quintens R, Van LL, Van SK, De HG, Lemaire K, Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010;16:2090–8.
   PubMed Web of Science ®Google Scholar
• Rismo R, Olsen T, Cui G, Christiansen I, Florholmen J, Goll R. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol 2012;47:538–47.
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's disease Study. Gastroenterology 1976;70:439–44.
   PubMed Web of Science ®Google Scholar
• Cui G, Olsen T, Christiansen I, Vonen B, Florholmen J, Goll R. Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use. Scand J Clin Lab Invest 2006;66:249–59.
   PubMed Web of Science ®Google Scholar
• Goll R, Olsen T, Cui G, Florholmen J. Evaluation of absolute quantitation by nonlinear regression in probe-based real-time PCR. BMC Bioinformatics 2006;7:107.
   PubMed Web of Science ®Google Scholar
• Goll R, Gruber F, Olsen T, Cui G, Raschpichler G, Buset M, Helicobacter pylori stimulates a mixed adaptive immune response with a strong T-regulatory component in human gastric mucosa. Helicobacter 2007;12:185–92.
   PubMed Web of Science ®Google Scholar
• Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101–8.
   PubMed Web of Science ®Google Scholar
• Cui G, Goll R, Olsen T, Steigen SE, Husebekk A, Vonen B, Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. Cancer Immunol Immunother 2007;56:985–95.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433–42.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383–95.
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van AG, Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295–301.
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van AG, Caenepeel P, Vergauwe P, De VM, Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463–8.
   PubMed Web of Science ®Google Scholar
• Ricciardelli I, Lindley KJ, Londei M, Quaratino S. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. Immunology 2008;125:178–83.
   PubMed Web of Science ®Google Scholar
• Li Z, Arijs I, De Hertogh G, Vermeire S, Noman M, Bullens D, Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis 2010;16:1299–310.
   PubMed Web of Science ®Google Scholar
• Liu Z, Jiu J, Liu S, Fa X, Li F, Du Y. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion. J Autoimmun 2007;29:187–94.
   PubMed Web of Science ®Google Scholar
• Olsen T, Goll R, Cui G, Christiansen I, Florholmen J. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine 2009;46:222–7.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Giese T, Hermann E, Zeuzem S, Meuer SC, Stallmach A. Predictive value of mucosal TNF transcripts in steroid refractory Crohn's disease patients receiving intensive immunosuppressive therapy. Inflamm Bowel Dis 2007;13:65–70.
   PubMed Web of Science ®Google Scholar
• Verdier J, Begue B, Cerf-Bensussan N, Ruemmele FM. Compartmentalized expression of Th1 and Th17 cytokines in pediatric inflammatory bowel diseases. Inflamm Bowel Dis 2012;18:1260–6.
   PubMed Web of Science ®Google Scholar
• Florholmen J, Fries W. Candidate mucosal and surrogate biomarkers of inflammatory bowel disease in the era of new technology. Scand J Gastroenterol 2011;46:1407–17.
   PubMed Web of Science ®Google Scholar
• Arsenescu R, Bruno ME, Rogier EW, Stefka AT, McMahan AE, Wright TB, Signature biomarkers in Crohn's disease: toward a molecular classification. Mucosal Immunol 2008;1:399–411.
   PubMed Web of Science ®Google Scholar